CD19-CAR-DNT / Ruichuang Bio, Zhejiang Ruijiamei Biotech - LARVOL DELTA

Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL (clinicaltrials.gov) - P1 | N=12 | Recruiting | Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

New P1 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19